All Stories

  1. Improving conformational stability and bacterial membrane interactions of antimicrobial peptides with amphipathic helical structure
  2. Investigating the impact of charge and hydrophilicity on peptide-mucin interactions using a simple mucin model
  3. Systematic Search for Blood–Brain Barrier Modulating Peptides Based on Exhaustive E-Cadherin Domain–Domain Docking
  4. Directing cell delivery to murine atherosclerotic aortic lesions via targeting inflamed circulatory interface using nanocarriers
  5. Formulation development and feasibility of AAV5 as a lyophilized drug product
  6. Innovative CDR grafting and computational methods for PD-1 specific nanobody design
  7. Peptide Design for Enhanced Anti-Melanogenesis: Optimizing Molecular Weight, Polarity, and Cyclization
  8. Delivery of Neuroregenerative Proteins to the Brain for Treatments of Neurodegenerative Brain Diseases
  9. Exploring How Antibody Format Drives Clearance from the Brain
  10. Mechanism of the blood-brain barrier modulation by cadherin peptides
  11. Selective Uptake of Macromolecules to the Brain in Microfluidics and Animal Models Using the HAVN1 Peptide as a Blood-Brain Barrier Modulator
  12. Enhancing Antibody Exposure in the Central Nervous System: Mechanisms of Uptake, Clearance, and Strategies for Improved Brain Delivery
  13. M. tuberculosis Transcription Machinery: A Review on the Mycobacterial RNA Polymerase and Drug Discovery Efforts
  14. Spermidine/Spermine N1-Acetyltransferase 1 (SAT1)—A Potential Gene Target for Selective Sensitization of Glioblastoma Cells Using an Ionizable Lipid Nanoparticle to Deliver siRNA
  15. Structural Design and Synthesis of Novel Cyclic Peptide Inhibitors Targeting Mycobacterium tuberculosis Transcription
  16. Immune Modulation by Antigenic Peptides and Antigenic Peptide Conjugates for Treatment of Multiple Sclerosis
  17. Enhancing Intestinal Absorption of a Model Macromolecule via the Paracellular Pathway using E-Cadherin Peptides
  18. Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles
  19. Non-invasive Brain Delivery and Efficacy of BDNF in APP/PS1 Transgenic Mice
  20. Noninvasive Brain Delivery and Efficacy of BDNF to Stimulate Neuroregeneration and Suppression of Disease Relapse in EAE Mice
  21. Improving In Vivo Brain Delivery of Monoclonal Antibody Using Novel Cyclic Peptides
  22. In Vivo Brain Delivery and Brain Deposition of Proteins with Various Sizes
  23. Validation of Cadherin HAV6 Peptide in the Transient Modulation of the Blood-Brain Barrier for the Treatment of Brain Tumors
  24. Orf239342 from the mushroom Agaricus bisporus is a mannose binding protein
  25. Methotrexate disposition, anti-folate activity and efficacy in the collagen-induced arthritis mouse model
  26. Protein PEGylation for cancer therapy: bench to bedside
  27. Conjugates of Cell Adhesion Peptides
  28. Enhancing In Vivo Brain Delivery of Peptide and Protein Molecules in Animal Models
  29. Drug Delivery
  30. Physiological, Biochemical, and Chemical Barriers to Oral Drug Delivery
  31. Meet Our Regional Editor:
  32. Prodrug strategies for brain delivery
  33. Modulation of Intercellular Junctions by Cyclic-ADT Peptides as a Method to Reversibly Increase Blood–Brain Barrier Permeability
  34. Routes of Administration and Dose Optimization of Soluble Antigen Arrays in Mice with Experimental Autoimmune Encephalomyelitis
  35. Co-Delivery of Autoantigen and B7 Pathway Modulators Suppresses Experimental Autoimmune Encephalomyelitis
  36. Pathways and progress in improving drug delivery through the intestinal mucosa and blood–brain barriers
  37. Structure, Size, and Solubility of Antigen Arrays Determines Efficacy in Experimental Autoimmune Encephalomyelitis
  38. Modulation of Blood–Brain Barrier Permeability in Mice Using Synthetic E-Cadherin Peptide
  39. 1H, 13C and 15N backbone assignment of the EC-1 domain of human E-cadherin
  40. Hyaluronic Acid Graft Polymers Displaying Peptide Antigen Modulate Dendritic Cell Response in Vitro
  41. Codelivery of antigen and an immune cell adhesion inhibitor is necessary for efficacy of soluble antigen arrays in experimental autoimmune encephalomyelitis
  42. Suppression of MOG- and PLP-induced experimental autoimmune encephalomyelitis using a novel multivalent bifunctional peptide inhibitor
  43. Single-step grafting of aminooxy-peptides to hyaluronan: A simple approach to multifunctional therapeutics for experimental autoimmune encephalomyelitis
  44. Biodegradable Nanoparticles Surface Modification Techniques With cIBR Peptide Targeting to LFA-1 Expressing Leukemic Cells
  45. Controlling immune response and demyelination using highly potent bifunctional peptide inhibitors in the suppression of experimental autoimmune encephalomyelitis
  46. Vaccinelike and Prophylactic Treatments of EAE with Novel I-Domain Antigen Conjugates (IDAC): Targeting Multiple Antigenic Peptides to APC
  47. Peptide Delivery
  48. Chemical Pathways of Peptide and Protein Degradation
  49. Methotrexate (MTX)–cIBR Conjugate for Targeting MTX to Leukocytes: Conjugate Stability and In Vivo Efficacy in Suppressing Rheumatoid Arthritis
  50. Immune modulating peptides for the treatment and suppression of multiple sclerosis
  51. Improving the stability of the EC1 domain of E-cadherin by thiol alkylation of the cysteine residue
  52. Vaccine-like Controlled-Release Delivery of an Immunomodulating Peptide To Treat Experimental Autoimmune Encephalomyelitis
  53. I-Domain-Antigen Conjugate (IDAC) for Delivering Antigenic Peptides to APC: Synthesis, Characterization, and in Vivo EAE Suppression
  54. Suppression of EAE and prevention of blood–brain barrier breakdown after vaccination with novel bifunctional peptide inhibitor
  55. Peptides and Proteins for Treatment and Suppression of Type 1 Diabetes
  56. Rapid Identification of Fluorochrome Modification Sites in Proteins by LC ESI-Q-TOF Mass Spectrometry
  57. Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics
  58. Calcium Condensed LABL-TAT Complexes Effectively Target Gene Delivery to ICAM-1 Expressing Cells
  59. Antigen-specific blocking of CD4-Specific immunological synapse formation using BPI and current therapies for autoimmune diseases
  60. Nanoparticles Targeting Dendritic Cell Surface Molecules Effectively Block T Cell Conjugation and Shift Response
  61. Controlling Ligand Surface Density Optimizes Nanoparticle Binding to ICAM-1
  62. Enhancement of Drug Absorption through the Blood−Brain Barrier and Inhibition of Intercellular Tight Junction Resealing by E-Cadherin Peptides
  63. MODULASI JUNCTION ANTAR SEL MENGGUNAKAN PEPTIDA KADHERIN UPAYA MENINGKATKAN PENGHANTARAN OBAT
  64. Peptide-mediated targeted drug delivery
  65. ChemInform Abstract: Oxazolophanes as Masked Cyclopeptide Alkaloid Equivalents: Cyclic Peptide Chemistry without Peptide Couplings.
  66. ChemInform Abstract: Delocalized Carbanions in Synthesis
  67. LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery
  68. A Peptide from the Beta-strand Region of CD2 Protein that Inhibits Cell Adhesion and Suppresses Arthritis in a Mouse Model
  69. ChemInform Abstract: Synthesis of an Esterase-Sensitive Cyclic Prodrug of a Model Hexapeptide Having Enhanced Membrane Permeability and Enzymic Stability Using a 3-(2′-Hydroxy-4′,6′-dimethylphenyl)-3,3-Dimethylpropionic Acid Promoiety
  70. ChemInform Abstract: Synthesis of an Esterase-Sensitive Cyclic Prodrug of a Model Hexapeptide Having Enhanced Membrane Permeability and Enzymatic Stability Using an Acyloxyalkoxy Promoiety
  71. ChemInform Abstract: Steric Hindrance is a Key Factor in the Coupling Reaction of (Acyloxy) Alkyl-α-halides with Phenols to Make a New Promoiety for Prodrugs.
  72. ChemInform Abstract: Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a Therapeutic Approach to Inflammation and Autoimmune Diseases
  73. cIBR Effectively Targets Nanoparticles to LFA-1 on Acute Lymphoblastic T Cells
  74. Immune response to controlled release of immunomodulating peptides in a murine experimental autoimmune encephalomyelitis (EAE) model
  75. Antigen-Specific Suppression of Experimental Autoimmune Encephalomyelitis by a Novel Bifunctional Peptide Inhibitor: Structure Optimization and Pharmacokinetics
  76. The Role of Thiols and Disulfides on Protein Stability
  77. The Role of Covalent Dimerization on the Physical and Chemical Stability of the EC1 Domain of Human E-Cadherin
  78. Solution structure of a novel T-cell adhesion inhibitor derived from the fragment of ICAM-1 receptor: Cyclo(1,8)-Cys-Pro-Arg-Gly-Gly-Ser-Val-Cys
  79. Adhesion of pancreatic beta cells to biopolymer films
  80. Characterization of Multiple Stable Conformers of the EC5 Domain of E-cadherin and the Interaction of EC5 with E-cadherin Peptides
  81. ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells
  82. Effect of Modification of the Physicochemical Properties of ICAM-1-Derived Peptides on Internalization and Intracellular Distribution in the Human Leukemic Cell Line HL-60
  83. The aqueous conformation of cyclo(1,6)Ac-Cys-Arg-Gly-Asp-Phe-Pen-NH2
  84. Conformational analysis of cyclo(2,9)-Ac-QCRSVEGSCG-OH from the C-terminal loop of human growth hormone
  85. Inhibition of homotypic adhesion of T-cells: secondary structure of an ICAM-1-derived cyclic peptide
  86. Evaluation of the physical stability of the EC5 domain of E-cadherin: Effects of pH, temperature, ionic strength, and disulfide bonds
  87. Prophylactic and therapeutic suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor
  88. Structural Modifications of ICAM-1 Cyclic Peptides to Improve the Activity to Inhibit Heterotypic Adhesion of T cells
  89. PLGA Nanoparticle−Peptide Conjugate Effectively Targets Intercellular Cell-Adhesion Molecule-1
  90. Mechanism of Internalization of an ICAM-1-Derived Peptide by Human Leukemic Cell Line HL-60: Influence of Physicochemical Properties on Targeted Drug Delivery
  91. ICAM-1 Peptide Inhibitors of T-cell Adhesion bind to the allosteric site of LFA-1. An NMR Characterization
  92. ICAM-1 Peptide Inhibitors of T-cell Adhesion bind to the allosteric site of LFA-1. An NMR Characterization
  93. Sequence Recognition of ?-LFA-1-derived Peptides by ICAM-1 Cell Receptors: Inhibitors of T-cell Adhesion
  94. Suppression of Type 1 Diabetes in NOD Mice by Bifunctional Peptide Inhibitor: Modulation of the Immunological Synapse Formation
  95. Antigen-Specific Suppression of Experimental Autoimmune Encephalomyelitis by a Novel Bifunctional Peptide Inhibitor
  96. Cell Adhesion Molecules for Targeted Drug Delivery
  97. Synthesis and chemical stability of a disulfide bond in a model cyclic pentapeptide: Cyclo(1,4)‐Cys‐Gly‐Phe‐Cys‐Gly‐OH
  98. Cell Adhesion Molecules for Targeted Drug Delivery
  99. Structure and Function of the Intercellular Junctions: Barrier of Paracellular Drug Delivery
  100. Characterization of Binding Properties of ICAM-1 Peptides to LFA-1: Inhibitors of T-cell Adhesion
  101. Effects of Amino Acid Chirality and the Chemical Linker on the Cell Permeation Characteristics of Cyclic Prodrugs of Opioid Peptides
  102. Deamidation of model β-turn cyclic peptides in the solid state
  103. Modulation of Cell Adhesion Molecules in Various Epithelial Cell Lines after Treatment with PP2 †
  104. Physiological, Biochemical, and Chemical Barriers to Oral Drug Delivery
  105. Drug Delivery
  106. Effects of An E-cadherin-Derived Peptide on the Gene Expression of Caco-2 Cells
  107. Design, structure and biological activity of β-turn peptides of CD2 protein for inhibition of T-cell adhesion
  108. Inhibition of ICAM-1/LFA-1-mediated heterotypic T-cell adhesion to epithelial cells: design of ICAM-1 cyclic peptides
  109. Reductive Alkylation of Lipase: Experimental and Molecular Modeling Approaches
  110. Expression, purification, and structural study of the EC4 domain of E-cadherin
  111. Solution structure of a peptide derived from the β subunit of LFA-1
  112. Syntheses of cyclic prodrugs of RGD peptidomimetics with various macrocyclic ring sizes: evaluation of physicochemical, transport and antithrombic properties
  113. Synthesis and comparison of physicochemical, transport, and antithrombic properties of a cyclic prodrug and the parent RGD peptidomimetic
  114. A Peptide Derived from LFA-1 Protein that Modulates T-cell Adhesion Binds to Soluble ICAM-1 Protein
  115. Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors
  116. Synthesis and stability study of a modified phenylpropionic acid linker-based esterase-sensitive prodrug
  117. Localized production of human E-cadherin-derived first repeat in Escherichia coli
  118. Synthesis of a novel cyclic prodrug of RGD peptidomimetic to improve its cell membrane permeation
  119. Structural and ICAM-1-Docking Properties of a Cyclic Peptide from the I-domain of LFA-1: An inhibitor of ICAM-1/LFA-1-mediated T-cell adhesion
  120. Molecular Dynamics Simulations of Conformational Behavior of Linear RGD Peptidomimetics and Cyclic Prodrugs in Aqueous and Octane Solutions
  121. Synthesis and conformational analysis of a coumarinic acid-based cyclic prodrug of an opioid peptide with modified sensitivity to esterase-catalyzed bioconversion
  122. Modeling alternative binding registers of a minimal immunogenic peptide on two class II major histocompatibility complex (MHC II) molecules predicts polarized T-cell receptor (TCR) contact positions
  123. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases
  124. Synthesis of Cyclic Prodrugs of Aggrastat and Its Analogue with a Modified Phenylpropionic Acid Linker
  125. Steric hindrance is a key factor in the coupling reaction of (acyloxy) alkyl-α-halides with phenols to make a new promoiety for prodrugs
  126. Synergistic inhibitory activity of α- and β-LFA-1 peptides on LFA-1/ICAM-1 interaction
  127. Rapid Determination of Substrate Specificity of Clostridium histolyticum  -Collagenase Using an Immobilized Peptide Library
  128. Regulation of Cadherin-Cadherin Interaction: Secondary Structure of the HAV and ADT Peptides Derived from Human E-Cadherin Sequence
  129. Utilization of ICAM-1 Peptide Conjugates for Drug Targeting to T-Cells
  130. Conjugation with L-Glutamate forin vivoBrain Drug Delivery
  131. Linear and cyclic LFA-1 and ICAM-1 peptides inhibit T cell adhesion and function
  132. Effect of Conformation on the Rate of Deamidation of Vancomycin in Aqueous Solutions
  133. Enhancement of Transport of D-Melphalan Analogue by Conjugation with L-Glutamate across Bovine Brain Microvessel Endothelial Cell Monolayers
  134. Comparison of the Solution Conformations of a Cell-Adhesive Peptide LBE and its Reverse Sequence EBL
  135. PEPTIDES DERIVED FROM ICAM-1 AND LFA-1 MODULATE T CELL ADHESION AND IMMUNE FUNCTION IN A MIXED LYMPHOCYTE CULTURE1
  136. Effect of conformation on the conversion of cyclo-(1,7)-Gly-Arg-Gly-Asp-Ser-Pro-Asp-Gly-OH to its cyclic imide degradation product
  137. Solution stability of linear vs. cyclic RGD peptides
  138. The effect of conformation on the solution stability of linear vs. cyclic RGD peptides
  139. Binding and internalization of an ICAM‐1 peptide by the surface receptors of T cells
  140. The effect of conformation on the membrane permeation of coumarinic acid‐ and phenylpropionic acid‐based cyclic prodrugs of opioid peptides
  141. The effect of conformation of the acyloxyalkoxy‐based cyclic prodrugs of opioid peptides on their membrane permeability
  142. Structural recognition of an ICAM‐1 peptide by its receptor on the surface of T cells: conformational studies of cyclo (1, 12)‐Pen‐Pro‐Arg‐Gly‐Gly‐Ser‐Val‐Leu‐Val‐Thr‐Gly‐Cys‐OH
  143. Synthesis and evaluation of the physicochemical properties of esterase‐sensitive cyclic prodrugs of opioid peptides using coumarinic acid and phenylpropionic acid linkers
  144. Synthesis and evaluation of the physicochemical properties of esterase‐sensitive cyclic prodrugs of opioid peptides using an (acyloxy)alkoxy linker
  145. A Ca2+binding cyclic peptide derived from the ?-subunit of LFA-1: inhibitor of ICAM-1 /LFA-1-mediated T-cell adhesion
  146. Molecular Structure of the Apical Junction Complex and Its Contribution to the Paracellular Barrier
  147. Separation and Analysis of Peptides and Proteins
  148. Modulation of Melphalan Resistance in Glioma Cells with a Peripheral Benzodiazepine Receptor Ligand−Melphalan Conjugate
  149. Prodrug strategies to enhance the intestinal absorption of peptides
  150. Synthesis of a Novel Esterase-Sensitive Cyclic Prodrug of a Hexapeptide Using an (Acyloxy)alkoxy Promoiety
  151. Synthesis of a Novel Esterase-Sensitive Cyclic Prodrug System for Peptides That Utilizes a “Trimethyl Lock”-Facilitated Lactonization Reaction
  152. Modulation of the Cellular Junction Protein E-Cadherin in Bovine Brain Microvessel Endothelial Cells by Cadherin Peptides
  153. Modulation of cellular adhesion in bovine brain microvessel endothelial cells by a decapeptide
  154. Derivatives of Melphalan Designed to Enhance Drug Accumulation in Cancer Cells
  155. Novel esterase-sensitive cyclic prodrugs of a model hexapeptide having enhanced membrane permeability and enzymatic stability
  156. Solution Structure of a Cyclic RGD Peptide That Inhibits Platelet Aggregation
  157. Structural requirements for intestinal absorption of peptide drugs
  158. Secondary Structure of the HAV Peptide Which Regulates Cadherin-Cadherin Interaction
  159. Separation and Analysis of Peptides and Proteins
  160. E-Cadherin Peptide Sequence Recognition by Anti-E-Cadherin Antibody
  161. Conformational study of cyclo[Gln-Trp-Phe-Gly-Leu-Met] as NK-2 antagonist by NMR and molecular dynamics
  162. Immobilized peptide arrays: A new technology for the characterization of protease function
  163. Conformational study of cyclo(1,5)-Ac-Pen-Arg-Gly-Asp-Cys-NH2 in water by NMR and molecular dynamics
  164. Delocalized Carbanions in Synthesis
  165. Oxazolophanes as masked cyclopeptide alkaloid equivalents: cyclic peptide chemistry without peptide couplings
  166. A new rearrangement of alkoxybenzyl anions
  167. The role of boron trifluoride etherate in reactions of lower order (Gilman) organocuprates
  168. Modeling of the homoeo domain suggests similar structure to repressors
  169. Effects of boron trifluoride etherate on higher order organocuprate reactions: substrate activation or cuprate modification?
  170. Sesquiterpenoid glycosides and an acetogenin glucoside from Lessingia glandulifera
  171. Kolavane diterpenoids of Vanclevea stylosa
  172. Grindelane diterpenoids from Isocoma tenuisecta
  173. Unexpected affects of Me3Si-X on reactions of higher order cyanocuprates
  174. Preparation and reactions of trianions from the dimethylphenols
  175. Five grindelane diterpenoids from Grindelia acutifolia
  176. Havardic acids A-F and havardiol, labdane diterpenoids from Grindelia havardii
  177. A new diterpenoid from Ericameria laricifolia
  178. A New Heterocyclic System from Salol and Phenylacetic Acid
  179. Preparation and reactions of dianions from cresols
  180. Labdane diterpenoids from Grindelia discoidea (asteraceae)
  181. 9,10-Anthracenedicarbaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] acetic acid hydrochloric acid trihydrate salt (bisantrene)
  182. Cardenolides and a lignan from asclepias subulata
  183. Diterpenoids and flavonoids from Grindelia discoidea
  184. Utilization of cell-adhesion peptides to improve drug delivery
  185. Cells activation modulates binding of an LFA-1 peptide to the T-cell adhesion receptors
  186. Synthesis of an Esterase-Sensitive Cyclic Prodrug of a Model Hexapeptide Having Enhanced Membrane Permeability and Enzymatic Stability Using an Acyloxyalkoxy Promoiety
  187. Synthesis of an Esterase-Sensitive Cyclic Prodrug of a Model Hexapeptide Having Enhanced Membrane Permeability and Enzymatic Stability Using a 3-(2'-Hydroxy-4',6'-Dimethylphenyl)-3,3-Dimethyl Propionic Acid Promoiety
  188. Inhibition of E-cadherin-mediated cell-cell adhesion by cadherin peptides